Want to look younger but don’t want to prod your face with injections? You’re not alone because it turns out plenty of youth seekers are consuming collagen via less invasive beauty techniques with Eve Health (ASX: EVE) reporting strong sales of their probiotic concentrate drinks, including those infused with collagen.
Such demand has seen Eve subsidiary Meluka Australia generate $750k in sales for the 6 months ended 31 December 2022. This represented a 34% increase to the previous corresponding period as Australians opened their wallets to health and wellness products over the holiday season.
The main driver behind the jump in revenue came from Meluka’s probiotic beverage range which are marketed to contain concentrated honey probiotics.
“Meluka Australia has had an impressive six-month period, with growth across Australia, North America and Japan,” said Meluka Australia CEO, Ben Rohr.
“Distribution and expansion plans are well progressed with new products expected to expand our brand awareness and grow sales accordingly.”
Given the impressive results over the past six months, Meluka has confirmed its ambitious plans to expand its range of Collagen Probiotic Concentrate drinks with the first product launched last month. This would see a further four collagen drinks launched before the end of March 2022.
Collagen is best known in beauty circles as a product that can be injected into the skin to maintain elasticity and firming as an anti-aging procedure.
Demand for such products has long come from Asian markets which Meluka is actively targeting. With such audiences primarily active on direct messaging channels, Meluka is set to launch a new eCommerce store on WhatsApp Commerce shortly,
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
- Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
- Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
- ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
Leave a Comment
You must be logged in to post a comment.